Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects

Oncology Reports

Volumn 26, Issue 1, 2011, Pages 255-264

  Yu, Bin ^a   Zhang, Yu ^a   Zhan, Yang ^a   Zha, Xiao ^b   Wu, Yonege ^a   Zhang, Xizhen ^a   Dong, Qingzhe ^a   Kong, Wei ^a   Yu, Xianghui ^a  

^a JILIN UNIVERSITY   (China)

^b SICHUAN CANCER HOSPITAL   (China)

Author keywords

Adenovirus; Breast cancer; Escherichia coli nitroreductase; HSV TK; hTERT; Internal ribosome entry site

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; NITROREDUCTASE; TELOMERASE REVERSE TRANSCRIPTASE; THYMIDINE KINASE; TRETAZICAR;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE TARGETING; GROWTH INHIBITION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SUICIDE GENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BREAST NEOPLASMS; CELL LINE, TUMOR; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; HELA CELLS; HUMANS; MICE; MICE, INBRED BALB C; SIMPLEXVIRUS; TELOMERASE; THYMIDINE KINASE;

EID: 79955867288     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1285     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thuns MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Bernard WS and Paul K: World Cancer Report. International Agency for Research on Cancer. Lyon, 2003.
3. Altaner C: Prodrug cancer gene therapy. Cancer Lett 270: 191-201, 2008.
4. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL and Abraham GN: The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283, 1993.
5. Immonen A, Vapalahti M, Tyynelä K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N and Ylä-Herttuala S: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther 10: 967-972, 2004 (Pubitemid 39419922)
6. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389-2401, 2000.
7. Uckert W, Kammertöns T, Haack K, Qin Z, Gebert J, Schendel DJ and Blankenstein T: Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther 9: 855-865, 1998. (Pubitemid 28197372)
8. Wolfert MA, Schacht EH, Toncheva V, Ulbrich K, Nazarova O and Seymour LW: Characterization of vectors for gene therapy formed by self-assembly of DNA with synthetic block co-polymers. Hum Gene Ther 7: 2123-2133, 1996. (Pubitemid 26400737)
9. Zhang YP, Sekirov L, Saravolac EG, Wheeler JJ, Tardi P, Clow K, Leng E, Sun R, Cullis PR and Scherrer P: Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties. Gene Ther 6: 1438-1447, 1999. (Pubitemid 29396732)
10. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419, 2003. (Pubitemid 37296260)
11. Seggewiss R and Dunbar CE: A new direction for gene therapy: intrathymic T cell-specific lentiviral gene transfer. J Clin Invest 115: 2064-2067, 2005. (Pubitemid 41134143)
12. Puck JM and Malech HL: Gene therapy for immune disorders: good news tempered by bad news. J Allergy Clin Immunol 117: 865-869, 2006.
13. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW and Sands MS: AAV vector integration sites in mouse hepatocellular carcinoma. Science 317: 477, 2007 (Pubitemid 47196106)
14. Dave UP, Akagi K, Tripathi R, Cleveland SM, Thompson MA, Yi M, Stephens R, Downing JR, Jenkins NA and Copeland NG: Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet 5: e1000491, 2009.
15. Yamamoto N, Hayashi Y, Kagami H, Fukui T, Fukuhara H, Tohnai I, Ueda M, Mizuno M and Yoshida J: Suicide gene therapy using adenovirus vector for human oral squamous carcinoma cell line in vitro. Nagoya J Med Sci 67: 83-91, 2005.
16. Määttä AM, Samaranayake H, Pikkarainen J, Wirth T and Ylä-Herttuala S: Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr Gene Ther 9: 356-367, 2009.
17. Wang ZX, Bian HB, Yang JS, De W and Ji XH: Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer. Cancer Biol Ther 8: 1480-1488, 2009.
18. Zhang Y, Yu XH, Zha X and Kong W: Adenovirus-mediated HSV-TK gene therapy using hTERT promoter in CNE cells in vitro. Chem Res Chinese U 25: 60-63, 2009.
19. Hu Z, Robbins JS, Pister A, Zafar MB, Zhang ZW, Gupta J, Lee KJ, Neuman K, Yun CO, Guise T and Seth P: A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy. Cancer Gene Ther 17: 235-243, 2010.
20. Song JS: Activity of the human telomerase catalytic subunit (hTERT) gene promoter could be increased by the SV40 enhancer. Biosci Biotechnol Biochem 68: 1634-1639, 2004.
21. Graham FL, Smiley J, Russell WC and Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74, 1977.
22. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC and Scardino PT: In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial. Hum Gene Ther 10: 1239-1249, 1999.
23. Klatzmann D, Valéry CA, Bensimon G, Marro B, Boyer O, Mokhtari K, Diquet B, Salzmann JL and Philippon J: A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 9: 2595-2604, 1998.
24. Schellingerhout D, Rainov NG, Breakefield XO and Weissleder R: Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther 7: 1648-1655, 2000.
25. Djeha AH, Hulme A, Dexter MT, Mountain A, Young LS, Searle PF, Kerr DJ and Wrighton CJ: Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther 7: 721-731, 2000. (Pubitemid 30314056)
26. Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP and Collins MK: Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 31: A2362-A2370, 1995.
27. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994
28. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ and Reddel RR: Protein composition of catalytically active human telomerase from immortal cells. Science 315: 1850-1853, 2007.
29. Wirth T, Kuhnel F and Kubicka S: Telomerase-dependent gene therapy. Curr Mol Med 5: 243-251, 2005.
30. Tang XJ, Wang YP, Zhou QH, Che GW Chen XH and Zhu DX: A study on selective killing effect of Hsv-tk/GCV driven by human telomerase catalytic subunit promoter on human lung cancer cell A549. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 24: 148-152, 2007
31. Song JS, Kim HP, Yoon WS, Lee KW, Kim MH, Kim KT, Kim HS and Kim YT: Adenovirus-mediated suicide gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter induced apoptosis of ovarian cancer cell line. Biosci Biotechnol Biochem 67: 2344-2350, 2003.
32. Song J, Kim C and Ochoa ER: Sleeping Beauty-mediated suicide gene therapy of hepatocellular carcinoma. Biosci Biotechnol Biochem 73: 165-168, 2009.
33. Schepelmann S, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Chen P, Marais R and Springer CJ: Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res 67: 4949-4955, 2007. (Pubitemid 46910203)
34. Douin V, Bornes S, Creancier L, Rochaix P, Favre G, Prats AC and Couderc B: Use and comparison of different internal ribosomal entry sites (IRES) in tricistronic retroviral vectors. BMC Biotechnol 4: 16, 2004.